Rafferty Asset Management LLC Sells 16,034 Shares of Eli Lilly and Company $LLY

Key Points

• Rafferty Asset Management LLC sold 16,034 shares of Eli Lilly and Company, decreasing its holdings by 17.9% to a total of 73,776 shares, valued at approximately $60.9 million.
• In recent insider transactions, CEO David A. Ricks purchased 1,632 shares at $644.77 each, increasing his stake in the company, while Director J Erik Fyrwald also acquired 1,565 shares.
• Eli Lilly's recent earnings report showed a 37.6% year-over-year increase in revenue, reaching $15.56 billion, and reported $6.31 EPS, beating analysts' estimates considerably.

Rafferty Asset Management LLC decreased its holdings in Eli Lilly and Company (NYSE:LLY - Free Report) by 17.9% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 73,776 shares of the company's stock after selling 16,034 shares during the quarter. Rafferty Asset Management LLC's holdings in Eli Lilly and Company were worth $60,932,000 as of its most recent SEC filing.

Several other institutional investors have also recently bought and sold shares of the business. J. Stern & Co. LLP raised its position in Eli Lilly and Company by 16.2% in the 1st quarter. J. Stern & Co. LLP now owns 4,049 shares of the company's stock valued at $3,344,000 after purchasing an additional 564 shares during the last quarter. Harvest Portfolios Group Inc. raised its position in Eli Lilly and Company by 2.7% in the 1st quarter. Harvest Portfolios Group Inc. now owns 126,155 shares of the company's stock valued at $104,193,000 after purchasing an additional 3,263 shares during the last quarter. Orion Capital Management LLC raised its position in shares of Eli Lilly and Company by 3.4% during the first quarter. Orion Capital Management LLC now owns 1,664 shares of the company's stock worth $1,374,000 after acquiring an additional 54 shares during the last quarter. Potomac Fund Management Inc. ADV bought a new stake in shares of Eli Lilly and Company during the first quarter worth $283,000. Finally, Caisse DE Depot ET Placement DU Quebec raised its position in shares of Eli Lilly and Company by 46.4% during the first quarter. Caisse DE Depot ET Placement DU Quebec now owns 765,030 shares of the company's stock worth $631,846,000 after acquiring an additional 242,560 shares during the last quarter. Institutional investors own 82.53% of the company's stock.

Insider Transactions at Eli Lilly and Company

In other Eli Lilly and Company news, CEO David A. Ricks bought 1,632 shares of the firm's stock in a transaction on Tuesday, August 12th. The stock was purchased at an average cost of $644.77 per share, with a total value of $1,052,264.64. Following the completion of the purchase, the chief executive officer owned 546,601 shares in the company, valued at approximately $352,431,926.77. The trade was a 0.30% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director J Erik Fyrwald bought 1,565 shares of the firm's stock in a transaction on Tuesday, August 12th. The stock was acquired at an average cost of $642.33 per share, with a total value of $1,005,246.45. Following the completion of the purchase, the director owned 74,578 shares of the company's stock, valued at approximately $47,903,686.74. This trade represents a 2.14% increase in their position. The disclosure for this purchase can be found here. In the last quarter, insiders acquired 4,514 shares of company stock valued at $2,894,841. Insiders own 0.14% of the company's stock.

Eli Lilly and Company Trading Down 2.2%

NYSE LLY opened at $696.08 on Tuesday. The stock has a 50-day simple moving average of $752.46 and a 200 day simple moving average of $788.70. The company has a market capitalization of $658.81 billion, a PE ratio of 45.50, a P/E/G ratio of 0.99 and a beta of 0.44. The company has a current ratio of 1.28, a quick ratio of 1.00 and a debt-to-equity ratio of 1.86. Eli Lilly and Company has a 12 month low of $623.78 and a 12 month high of $972.48.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The company reported $6.31 EPS for the quarter, beating analysts' consensus estimates of $5.59 by $0.72. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The business had revenue of $15.56 billion during the quarter, compared to the consensus estimate of $14.40 billion. During the same quarter in the prior year, the company posted $3.92 earnings per share. The firm's revenue was up 37.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. Research analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, September 10th. Shareholders of record on Friday, August 15th will be paid a $1.50 dividend. This represents a $6.00 dividend on an annualized basis and a yield of 0.9%. The ex-dividend date of this dividend is Friday, August 15th. Eli Lilly and Company's payout ratio is presently 39.22%.

Analyst Upgrades and Downgrades

LLY has been the subject of a number of recent research reports. Guggenheim dropped their target price on Eli Lilly and Company from $942.00 to $875.00 and set a "buy" rating for the company in a research report on Wednesday, August 13th. Daiwa Capital Markets downgraded Eli Lilly and Company from an "outperform" rating to a "neutral" rating and set a $700.00 target price for the company. in a research report on Sunday, August 17th. UBS Group dropped their target price on Eli Lilly and Company from $1,050.00 to $895.00 and set a "buy" rating for the company in a research report on Friday, August 8th. Leerink Partners restated a "market perform" rating and set a $715.00 target price on shares of Eli Lilly and Company in a research report on Thursday, August 7th. Finally, Deutsche Bank Aktiengesellschaft dropped their target price on Eli Lilly and Company from $1,010.00 to $900.00 and set a "buy" rating for the company in a research report on Monday, August 11th. One analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, seven have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $950.17.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.